J Rheumatol: Late Chronic Kidney Disease of Lupus nephritis

Advanced chronic kidney disease (CKD) increases the risk of developing end-stage renal disease (ESRD)The study was designed to determine the rate of lupus nephritis (LN) progression in ESRD and the factors that lead to decreased renal functionidentify patients with advanced LN-associated CKD from a long-term longitudinal queueLate CKD is defined as 3b (eGFR s 30-44ml/min/1.73m2) and 4th (eGFR s 15-29ml/min/1.73m2)Follow-up on all individuals until progression is MADE to ESRD or a final consultation, dividing the patients into "progressives" and "non-progressives"Comparing demographic, clinical, immunology and therapeutic indicators at baselineMulti-factor Cox regression analysis (time dependency and non-dependency) was performed to determine the predictors of progressincluded 118 patients (74 CKD 3b and 44 CKD 4)After an average of 6 years, there were 45 patient progressions (29 progressions for ESRD and 16 progressions from CKD 3b to CKD 4)After an average of 10 years, 73 patients ("non-progressives") did not see a significant decline in renal functionThe increase in serological activity at CKD diagnosis (high antidsofdna titer and lower complement C3/C4) and daily perpenitone dose after baseline were closely related to progressionThe treatment of renin angiotensin system (RAS) blockers was associated with a reduced risk of progressionLate-LN-associated CKD did not require dialysis because 62% of patients in the average 10-year follow-up did not progressSome of the predictors of the impact on progression of ESRD were identified